The Center for Breakthrough Medicines (CBM) and the University of Pennsylvania’s Gene Therapy Program (GTP) have signed a landmark collaboration agreement, to combine Penn’s knowledge and expertise in the development of Gene therapies with CBM’s manufacturing capacity and singular focus on advanced therapies.
This partnership is focused on moving therapeutics safely and rapidly from concept to clinic by connecting certain of Penn’s established Gene Therapy platforms with CBM’s manufacturing and analytical capacity. This combination will allow small biotech firms, universities, and large pharmaceutical companies to advance gene therapies from discovery to First-In-Human (FIH) studies with the potential for less risk and expense.
